Form D · Biotechnology
ONCOLYZE, INC.
New York, NY · CIK 0001917375
Offering snapshot reported Jul 7, 2022 · SEC filing
- Reported sold
- $425K Offering amount: $528K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 22, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 7, 2022 | Initial | $425,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $51K
- Finders' fees
- $0
- Form D file number
- 021-451445
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Ceros Financial Services, Inc. | 37869 |
Source: Form D, filed Jul 7, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Abeles | Director |
| Larry Altstiel | Executive |
| Barbara Carlin | Executive |
| Steven J. Evans | Director, Executive |
| James Foght | Director |
| Rosemary Mazanet | Director |
| Aleksandar Stojanovic | Executive |
| Alexander Zukiwski | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
845 Un Plaza, Apt. 61 B Attn: Steven J. Evans, M.D.
New York, NY, 10017
New York, NY, 10017